Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia

Core Insights - Samsung C&T and Samsung Electronics are making a strategic equity investment of $110 million in GRAIL to commercialize the Galleri multi-cancer early detection test in key Asian markets, starting with South Korea [1][4][6] Investment Details - The investment is priced at $70.05 per share, representing a 10% premium to the 15-day volume-weighted average price (VWAP) [1][24] - The investment is subject to customary closing conditions and regulatory approvals, expected to close in early 2026 [7] Strategic Collaboration - Samsung C&T will act as the exclusive partner to commercialize the Galleri test in South Korea, with potential expansion into Japan and Singapore [3][6] - GRAIL and Samsung Electronics will explore strategic collaborations, including genomic-lifestyle clinical research and integration of health data platforms [4][5] Market Expansion - The collaboration aims to establish a strong foothold for Samsung in the cancer screening field, enhancing access to innovative technologies in South Korea and across Asia [2][4] - Initial testing will occur in GRAIL's clinical laboratory located in Research Triangle Park, North Carolina [3] Technology and Innovation - The Galleri test can detect over 50 types of cancer through a simple blood draw, significantly improving early detection rates [12] - GRAIL's technology utilizes next-generation sequencing and machine learning to identify multiple cancer types at earlier stages [10]